SG3 Management’s Novavax NVAX Stock Holding History

SG3 Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,000	Closed	-$74K	–	685
2022 Q1	$74K	Buy	1,000 +500	+100%	+$44.6K	﹤0.01%	851
2021 Q4	$72K	Buy	+500	New	+$85.9K	﹤0.01%	935
2021 Q3	–	Sell	-2,000	Closed	-$425K	–	1162
2021 Q2	$425K	Buy	+2,000	New	+$366K	0.02%	686
2021 Q1	–	Sell	-2,000	Closed	-$223K	–	1386
2020 Q4	$223K	Sell	2,000 -500	-20%	-$53.1K	﹤0.01%	856
2020 Q3	$271K	Buy	+2,500	New	+$305K	0.01%	680

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SG3 Management's NVAX Position: Q2 2022 in Review

SG3 Management sold out of Novavax (NVAX) in Q2 2022, closing a stake of 1,000 shares — an estimated $74K sold.

SG3 Management first reported a position in NVAX in Q3 2020 and held it in 5 quarters. The position peaked at $425K in Q2 2021. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

SG3 Management reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
SG3 Management sold 1,000 Novavax shares in Q2 2022, an estimated $74K.
SG3 Management first reported a position in Novavax in Q3 2020 and held it in 5 quarters.
SG3 Management's Novavax position peaked at $425K in Q2 2021.
325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.